Dr. Nari Yun is a head of clinical/strategy of GI Innovation, Inc, a science-driven biotechnology company located in Korea, focusing on cancer and allergic disease. She is now leading the clinical and business development of GI Innovation’s pipeline. Dr. Yun began her career at Hanmi Pharmaceuticals, took the major role in clinical development programs for key assets including long-acting insulin, GLP-1 agonist and GLP-1/GCG dual agonist, contributing to licensing deal of those assets to Sanofi and Janssen. She also served as a strategic consultant in IQVIA (formerly known as IMS Consulting Group), delivering projects for key business decisions of pharma or biotech. Prior to joining to GI Innovation, she re-joined to Hanmi Pharmaceuticals as a clinical science leader and led the strategy development and clinical science of early-stage biologics. Dr. Yun is a registered pharmacist in Korea and was educated at School of Pharmacy, Sunkyunkwan University, where she received her PhD in pharmacology in 2012.